J
John D. Phillips
Researcher at University of Utah
Publications - 177
Citations - 7352
John D. Phillips is an academic researcher from University of Utah. The author has contributed to research in topics: Heme & Porphyria. The author has an hindex of 42, co-authored 170 publications receiving 6102 citations. Previous affiliations of John D. Phillips include Brookhaven National Laboratory & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Modelling and measuring flow and wind turbine wakes in large wind farms offshore
Rebecca Jane Barthelmie,Kurt Schaldemose Hansen,Sten Tronæs Frandsen,Ole Rathmann,J.G. Schepers,W. Schlez,John D. Phillips,K. Rados,Arthouros Zervos,E.S. Politis,P. Chaviaropoulos +10 more
TL;DR: In this article, the authors compare different types of models from computational fluid dynamics (CFD) to wind farm models in terms of how accurately they represent wake losses when compared with measurements from offshore wind farms.
Journal ArticleDOI
Biosynthesis of heme in mammals
TL;DR: The biochemistry, structural biology and the mechanisms of tissue-specific regulation are presented in this review along with the key features of the porphyric disorders.
Journal ArticleDOI
Identification of a human heme exporter that is essential for erythropoiesis.
John G. Quigley,Zhantao Yang,Mark T. Worthington,John D. Phillips,Kathleen M. Sabo,Daniel E. Sabath,Carl L. Berg,Shigeru Sassa,Brent L. Wood,Janis L. Abkowitz +9 more
TL;DR: It is demonstrated that human FLVCR exports cytoplasmic heme and hypothesize that humanFLVCR is required on developing erythroid cells to protect them from heme toxicity, the first description of a mammalian heme transporter.
Journal ArticleDOI
Iron Regulates the Intracellular Degradation of Iron Regulatory Protein 2 by the Proteasome
TL;DR: Iron regulation by iron in rat hepatoma and human HeLa cells and Pulse-chase experiments demonstrated that iron resulted in a 3-fold increase in the degradation rate of IRP2, suggesting the involvement of the proteasome in iron-mediated IRp2 proteolysis.
Journal ArticleDOI
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Manisha Balwani,Eliane Sardh,Paolo Ventura,Paula Aguilera Peiró,David C. Rees,Ulrich Stölzel,D. Montgomery Bissell,Herbert L. Bonkovsky,Jerzy Windyga,Karl E. Anderson,Charles J. Parker,Samuel M. Silver,Sioban Keel,Jiaan-Der Wang,Penelope E. Stein,Pauline Harper,Daphne Vassiliou,Bruce Wang,John D. Phillips,Aneta Ivanova,Janneke G. Langendonk,Raili Kauppinen,Elisabeth I. Minder,Yutaka Horie,Craig Penz,Jihong Chen,Shangbin Liu,John J. Ko,Marianne T. Sweetser,Pushkal Garg,Akshay Vaishnaw,Jae B. Kim,Amy Simon,Laurent Gouya,Envision Investigators +34 more
TL;DR: Givosiran led to lower levels of urinary ALA and porphobilinogen, fewer days of hemin use, and better daily scores for pain than placebo, and the increased efficacy was accompanied by a higher frequency of hepatic and renal adverse events.